Related Experiment Videos
NIH pre-clinical screening program: overview and current status.
Angelo Izzo1, Lise Brandt, Todd Lasco
1Department of Microbiology, Colorado State University, Immunology and Pathology, Mycobacterial Research Laboratories, 1682 Campus Delivery, Fort Collins 80523-1682, USA. angelo.izzo@colostate.edu
Tuberculosis (Edinburgh, Scotland)
|February 3, 2005
Summary
The rise in tuberculosis cases necessitates improved vaccines beyond M. bovis BCG. Researchers are actively screening novel tuberculosis vaccine candidates to address this urgent global health need.
Area of Science:
- Immunology
- Infectious Diseases
- Vaccinology
Background:
- Global increase in Mycobacterium tuberculosis cases necessitates more effective tuberculosis vaccines.
- The current M. bovis BCG vaccine has limitations, creating a need for alternative strategies.
- The National Institutes of Health initiated a call for new tuberculosis vaccine development in 1996.
Purpose of the Study:
- To screen and evaluate novel vaccine candidates against tuberculosis.
- To identify promising new strategies for tuberculosis prevention.
Main Methods:
- A comprehensive screening program was established at Colorado State University.
- A wide range of novel vaccine candidates were tested.
Main Results:
- The screening program has evaluated numerous potential new tuberculosis vaccines.
- Data on the efficacy of various novel candidates are being generated.
Conclusions:
- The ongoing screening efforts are crucial for advancing tuberculosis vaccine development.
- Identifying superior alternatives to M. bovis BCG is a key objective.